License Revenue was Stoke Therapeutics’s largest product and service line in fiscal 2024, bringing in $29.40M of $36.60M (80%).
| Product and Service | FY 2024 |
|---|---|
| License Revenue | $29.40M |
| Service Revenue | $7.20M |
| Total | $36.60M |
Stoke Therapeutics brought in $36.60M from its two product and service lines in fiscal 2024, the year ended December 31, 2024. License Revenue was the largest at $29.40M (80.3%), ahead of Service Revenue at $7.20M (19.7%).
Stoke Therapeutics (STOK) reports its revenue by product and service. In fiscal 2024, License Revenue was its largest product and service line, bringing in $29.40M (80.3% of the total), followed by Service Revenue at $7.20M (19.7%).
License Revenue was Stoke Therapeutics' largest product and service line in fiscal 2024, bringing in $29.40M, or 80.3% of the $36.60M total across its two product and service lines.
Every figure comes from Stoke Therapeutics' annual financial filings, as reported. Each line keeps the name Stoke Therapeutics gives it, and years follow its fiscal calendar.
Stoke Therapeutics' revenue by product and service goes back to fiscal 2024, with figures through fiscal 2024. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.